Mortality/Cancer risk/F1/Genetic effects/Gonadal dose
The Atomic Bomb Casualty Commission (ABCC) and its successor Radiation Effect Research Foundation (RERF) has over the years conducted many studies to determine possible genetic effects of atomic bomb radiation among the offspring of atomic bomb survivors. Findings concerning mortality and cancer incidence of the offspring are summarized in this chapter.
F1 POPULATION AND DOSIMETRY
The F1 cohort population currently consists of about 72,000 children (F1) born alive after 1 May to the survivors of the atomic bombings of Hiroshima and Nagasaki (Table 1 )'). This cohort specifically excludes the children exposed in utero and born before 1 May 1946. These are included in a separate in-utero sample as described elsewhere. The F1 population was originally defined as children born from May 1946 through December 1958 to proximally exposed (<2,000 m from the hypocenter) survivors and controls2), totaling about 50,000 children. The controls were age-, sex-, and city-matched children born to distally exposed (>2,500 m from the hypocenter) parents and to parents who were not in either Hiroshima or Nagasaki at the time of the bombings. Children born to parents who were within 2,001-2,500 m from the hypocenter were excluded because of the difficulty anticipated in estimating the low dose exposures at this distance and because of little information to be expected relative to the considerable amount of effort needed to follow a large number of children born to such parents. Subsequently, the cohort was expanded to include additional 22,000 children born between 1959 and 1984. Further details of the sample selection are available1,3) Dosimetry for A-bomb radiation exposure used formerly genetic studies at ABCC/RERF were based on the T65DR gonadal dose which was developed at the Oak Ridge National Laboratory. Recently the DS86 gonadal dose became available as a result of a reassessment of atomic bomb radiation. The DS86 dose system is based on the revised estimates of the radiation spectrum and amount of radiation released by the bombs, its attenuation with distance from the hypocenter and physical shielding, body position and ATB, orientation as well as the further attenuation by the intervening tissues. As seen in Table 1 , DS86 dose estimates are not available for a proportion of the parents of the children in the F, study largely because of the lack of sufficient information for all the parameters necessary for the DS86 system. Two reports were previously published using the T65DR dose estimates with RBE = 54,5
Using DS86 doses, cancer incidence in the first 20 years of life among the children of atomic bomb survivors has been analyzed'). Also, analysis of mortality based on the DS86 dose estimates is in progress3). In the studies using DS86 doses, an RBE of 20 is used to estimate the gonadal dose. The maximum RBE is considered to be 10-45 for genetic end-points in mammalian systems 6) or less than this? . At present the assumption of RBE does not influence the results much because of the very small neutron component in the new DS86 dose. Also, in the two new studies 1,3), ad hoc doses were used for some of the children for whom DS86 doses were not available. About 90% of the children with ad hoc dose were considered to have been exposed to X0.01 Sv, and comprised 6% of total children in the analysis.
MORTALITY FOR 1946-85
The children of A-bomb survivors are followed for vital status by checking koseki (family registration) records and, if found dead, causes of death are obtained from death certificate schedules. Ascertainment of dath is regarded virtually complete owing to the unique family registration system in Japan. Based on observations of the children born from May 1946 through 1958 (originally selected sample) and T65 dose estimates, risk coefficients associated with parental exposure were positive, but no significant increase in mortality was noted following parental exposure to atomic bomb radiation through 1980 (Table 2)4,5> In the study of mortality for 1946-19853), the DS86 dose is used for the expanded cohort.
As of the end of 1985, members born in 1946 had reached 39 years of age, whereas 27% of the children born to the exposed parents during 1966 and 1984 had not yet reached their 20th birthday. Still 76% of all deaths observed in 1946-85 occurred at ages of between 0 and 4 years. Therefore, findings from the new analysis are expected to be similar to those from the previous reports4,5) It should be noted that there are factors other than radiation that need to be considered in interpreting mortality findings. For example, the parents of the exposed children are older and considered less favorable in terms of socioeconomic status compared with those of the non exposed children. It is conceivable that the demographic and socioeconomic differences, rather than radiation itself, may lead to an appreciably inflated mortality in the exposed children. Other confounding factors include birth weight of an infant and parity of the mother. The possible role of these non-radiation factors is examined in the recent analysis.
CANCER INCIDENCE FOR 1946-82
In the original sample of about 50,000 F1 children, 36 leukemia incidence cases were identified during 1946-799). No significant excess risk for leukemia was found among the children of the exposed parents at any age during the period of (Table 3) .
The most recent studyl) on cancer risk included children born 1946 through 1982, a total of 72,216 individuals. The rationale for this study was that the frequency of cancer of relatively early onset might indicate the genetic effects of atomic bomb radiation exposure. As of 1982, 80% of F1 children were at least 20 years old. Cancer cases were ascertained through death certificates and the tumor registries in Hiroshima and Nagasaki. As described above, the ascertainment of fatal cancers is considered almost complete. However, the tumor registries were started in 1957 in Hiroshima and in 1958 in Nagasaki, and it is impossible to sytematically identify all cancers occurring in people who have left the tumor registry reporting areas. PY is person-years. [ 1 is average PY. Adjusted rates for city, sex, and year of birth were calculated per 105 PY by the indirect standardization method using total sample as a standard. At ages less than 20 years, a total of 92 cancer cases were observed from May 1946 through December 1982 in the F1 population (Table 4) . No statistically significant relationship was observed between cancer risk and conjoint parental gonadal dose. Of these 92 cancer cases, only 19 cases (about 20%) were considered to have "heritable" tumors. The latter tumors were defined based on a review of the literature and included the tumors listed in Table 5 . A significant proportion of these heritable childhood tumors, i.e. retinoblastoma and Wilms' tumor, are known to arise on the basis of a mutant gene inherited from one parent plus a second somatic cell mutation involving the allele of this gene10). No increased risk associated with parental gonadal dose was found for these heritable tumors.
After examining the occurrence of cancer in the 19 nuclear families of individuals with heritable cancers (38 parents, 57 siblings, and 8 children), seven cancer cases (one of each of the urinary bladder, maxillary sinus, thyroid, pancreas, esophagus, colon, and liver) were .observed in the parents. No cancer cases were noted among the siblings and children. The remainder of cancer cases observed in the F1 population, i.e., thirty-three leukemia cases (35.9%) and 40 other types of cancer (43.507o), may be considered largely due to somatic mutations occurring after birth.
COMMENTS
To date no significantly increased mortality has been found following parental exposure to atomic bomb radiation. In mouse studies sperm cells are known to be more sensitive to radiation exposure than sperm atogonia7). Unfortunately there is no information of untoward pregnancy outcomes including congenital malformations, stillbirths and early death among those early births that occurred in 1946 and 1947. No statistically significant radiation-dose related increase was found in the frequency of untoward pregnancy outcomes in the birth from 1948 to 19538). It also is to be noted that the risk based on the conjoint parental dose from atomic bomb survivors is referred to as zygotic while the risk based on a single parent exposure in the mouse experiment is referred to as gametic7)
.
Among the first generation of children born to A-bomb survivors, no cancer risk attributable to parental radiation exposure has been demonstrated. The mean gonadal dose in the exposed (>_ 0.01 Sv) group was 0.435 Sv. The rationale for investigating cancer risk prior to age 20 in the F1 population was that an increased cancer risk due to parental radiation exposure should be observable in forms of childhood cancer rather than in adult-type tumors. Representative of a rare form of genetically associated cancer, retinoblastoma is expected to occur at a rate of about 5 cases per 100,000 persons in the general population" (Table 5 ). Based on our studies, in which no significant increase of cancer risk (at ages G 20 years) was observed with increasing dose, the genetic effect on cancer risk due to A-bomb radiation exposure is considered to be extremely low. However, most tumors in the offspring of irradiated male or female mice studiedly are considered adult-onset tumors in humans. This suggests that continued follow-up is necessary for the F1 population, the oldest members of whom have just started to enter cancer-prone age groups.
While no significantly increased cancer risk under age 20 has been observed in the F1 population of atomic bomb survivors, other workers have reported contradictory observations. Shiono et al. indicated that preconceptual maternal exposure results in a relative risk of 2.61 (p=0.021)12). Their "medium" exposure was in the range of 0.7-3.0 mGy of cumulative dose to the ovaries and "high" exposure in 3.0 mGy or more. Recently Gardner et al. 13 ) reported raised incidence of leukemia and non-Hodgkin's lymphoma. in children of fathers employed at the Sellafield Nuclear power plant in England. The estimated relative risk was 2.44 for children of fathers employed at Sellafield at their conception. It was especially high (6.42) for children of fathers who were exposed to radiation during 6 months prior to conception and who received a total preconceptual ionizing radiation dose of 100 mSv or more, suggesting that the increased risk of leukemia may be related to radiation-induced mutations in post-spermatogonial cells. Our data are unclear about this point because of the rarity of leukemia cases and the limited number of children born from May 1945 to December 1946, i.e., those presumed to have been conceived during the 6 months after the bombing. Also, radiation exposure in the A-bomb survivors results from a single acute dose of radiation whereas the fathers at the Sellafield plant were exposed to continuous low-level radiation, making it difficult to compare results from the Sellafield study with ours14). On the basis of the DS86 dose schedule, Neel et al. have calculated an estimate l of the genetic doubling dose of acute radiation for humans, 1.7 Sv 2.2 Svs)
